

A1
This application is a continuation of PCT/US96/12389, filed July 29, 1996,
now pending, which is continuation-in-part of U.S. Patent Application Serial No. 08/509,254,
filed July 31, 1995, now U.S. Patent No. 5,788,963, the entire disclosure of which is
incorporated herein by reference.

IN THE CLAIMS:

Please amend claims 23-24 as follows:

A2
Sully
4B1
23. (amended) A composition, comprising: isolated human dendritic
cells which [following exposure] have been exposed, *in vitro*, to a prostate [cancer] tissue
antigen [have been cryopreserved].

24. (amended) The composition according to claim 23, in which the
[dendritic cells were cryopreserved following exposure to a] prostate [cancer] tissue antigen
is [selected from the group consisting of] a lysate of LNCaP cells, a membrane preparation of
LNCaP cells, a lysate of prostate tumor cells of the prostate cancer patient, isolated prostate
specific membrane antigen (PSMA), purified prostate specific membrane antigen (PSMA), a
peptide having the amino acid sequence LLHETDSAV (SEQ. ID. NO. 1), a peptide having
the amino acid sequence ALFDIESKV (SEQ. ID. NO. 2), a peptide having the amino acid
sequence XL(or M)XXXXXXV(or L) (SEQ. ID. NO. 3), where X represents any amino acid,
purified prostate specific antigen (PSA), [and] or a purified prostate mucin antigen
recognized by monoclonal antibody PD41.

Please add the following new claims 27-30.

A3
cont'd.
27. (new) The composition according to claim 23, in which the prostate
tissue antigen is:

A3
Cont'd.

WLCAGALVL (SEQ. ID. NO. 4); VLAGGFLL (SEQ. ID. NO. 5);
ELAHYDVLL (SEQ. ID. NO. 6); NLNGAGDPL (SEQ. ID. NO. 7);
TLRVDCTPL (SEQ. ID. NO. 8); VLRMMNDQL (SEQ. ID. NO. 9);
PMFKYHLTV (SEQ. ID. NO. 10); NMKAFLDEL (SEQ. ID. NO. 11);
LMYSLVHNL (SEQ. ID. NO. 12); MMNDQLMFL (SEQ. ID. NO. 13);
EGDLVYVNY (SEQ. ID. NO. 14); AGDPLTPGY (SEQ. ID. NO. 15);
RVDCTPLMY (SEQ. ID. NO. 16); LFEPPPPGY (SEQ. ID. NO. 17);
TYELVEKFY (SEQ. ID. NO. 18); AGESFPGIY (SEQ. ID. NO. 19);
WGEVKRQIY (SEQ. ID. NO. 20); IVRSFGTLKKE (SEQ. ID. NO. 21);
DELKAENIKKF (SEQ. ID. NO. 22); KSLYESWTKKS (SEQ. ID. NO. 23);
AYINADSSI (SEQ. ID. NO. 24); KYADKIYSI (SEQ. ID. NO. 25);
GYYDAQKLL (SEQ. ID. NO. 26); TYSVSFDSL (SEQ. ID. NO. 27);
NYARTEDFF (SEQ. ID. NO. 28); LYSDPADYF (SEQ. ID. NO. 29);
LPSIPVHPI (SEQ. ID. NO. 30); SPSPEFSGM (SEQ. ID. NO. 31);
VLVHPQWUL (SEQ. ID. NO. 32); KLQCVDLHV (SEQ. ID. NO. 33);
ALPERPSLY (SEQ. ID. NO. 34); JVGGECEK (SEQ. ID. NO. 35);
QVHPQKVTK (SEQ. ID. NO. 36); VVHYRKWIK (SEQ. ID. NO. 37); or
CYASGWGSI (SEQ. ID. NO. 38).

Sulr
B2

28. (new) The composition according to claim 23, in which the dendritic cells, following exposure *in vitro* to the prostate tissue antigen, have been cryopreserved.

29. (new) The composition according to claim 28, in which the prostate tissue antigen is a lysate of LNCaP cells, a membrane preparation of LNCaP cells, a lysate of prostate tumor cells of the prostate cancer patient, isolated prostate specific membrane